Decernotinib

Decernotinib is an experimental drug that was under development for the treatment of rheumatoid arthritis. It is a selective inhibitor of Janus kinase 3 (JAK3), a protein that plays a crucial role in the immune response. Decernotinib was developed by Vertex Pharmaceuticals but its development was discontinued in 2016 due to safety concerns.

Mechanism of Action

Decernotinib works by selectively inhibiting the activity of JAK3. This protein is involved in the signaling pathways of various cytokines and growth factors that are important for immune response. By inhibiting JAK3, decernotinib reduces the inflammatory response that is characteristic of rheumatoid arthritis.

Clinical Trials

Several clinical trials were conducted to evaluate the safety and efficacy of decernotinib in patients with rheumatoid arthritis. However, the development of the drug was discontinued in 2016 due to safety concerns.

Safety Concerns

The development of decernotinib was discontinued due to safety concerns. In clinical trials, some patients experienced serious adverse events, including infections and changes in liver function tests. The risk of these adverse events was considered to outweigh the potential benefits of the drug.

See Also

• Janus kinase inhibitor
• Rheumatoid arthritis
• Vertex Pharmaceuticals

References

Decernotinib Resources
Latest articles Most recent articles Ongoing trials	Wikipedia